Skip to main content
PCSA
NASDAQ Life Sciences

Processa Names Gujrathi Executive Chair, Adds Generian FcRn Program, Extends Runway to 2H 2029

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$1.95
Mkt Cap
$5.177M
52W Low
$1.041
52W High
$10.843
52W Position info
87% above low
Off High info
82% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

PCSA sits 87% above its 52-week low of $1.041 on light trading volume (0.3× avg).

Summary

Processa appointed Vidya founder Sheila Gujrathi as Executive Chair, signed an option-based research collaboration with Generian for an oral FcRn program, and said its cash now lasts into the second half of 2029.


Key Events · Executive and Board Changes · PCSA

  • Gujrathi Named Executive Chair

    Sheila Gujrathi, M.D., Vidya's founder and a board member since the June 2026 acquisition, became non-employee Executive Chair on October 28, 2026. Justin Yorke resigned as chair but remains a director.

  • Generian FcRn Collaboration Signed

    Processa entered a research collaboration and exclusive option agreement with Generian Pharmaceuticals covering an oral macrocyclic peptide-based neonatal Fc receptor antagonist program for IgG-mediated autoimmune diseases.

  • Cash Runway Extended to 2H 2029

    Management expects current cash resources, including the approximately $200 million private placement done alongside the Vidya acquisition, to fund operations into the second half of 2029.

  • CSU Phase 2 Design Set

    The FDA cleared the IND for VT-7208 in chronic spontaneous urticaria; the planned trial is a 12-week, randomized, double-blind, placebo-controlled study of about 120 adults not controlled on H1 antihistamines.


Analysis · PCSA · Life Sciences

Fresh off the Vidya merger, Processa is installing new leadership and adding a second pipeline asset. Dr. Sheila Gujrathi, Vidya's founder, takes over as Executive Chair from Justin Yorke, who stays on the board — a signal the post-merger company will be run around the Vidya team and its BTK inhibitor VT-7208. The Generian deal adds an oral FcRn antagonist program on an option structure, so cash outlay is limited until the science matures. Most concretely, management now says the roughly $200 million raised alongside the Vidya acquisition funds operations into the second half of 2029, which removes near-term financing pressure. The FDA's clearance of the CSU IND was already reported today, so the new information here is governance, pipeline breadth and runway.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PCSA was trading at $1.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.2M. The 52-week trading range was $1.04 to $10.84. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PCSA - Latest Insights

PCSA
Nov 05, 2026, 8:10 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.85
Real-time Price: $1.83 info
Change: -$0.020 (-1%) info
Market Cap: $5.149M info
PCSA
Oct 29, 2026, 8:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $1.89
Real-time Price: $1.83 info
Change: -$0.060 (-3%) info
Market Cap: $5.149M info
PCSA
Oct 09, 2026, 4:03 PM EDT
Filing Type: PRE 14A
Importance Score:
7
Price at Filing: $1.47
Real-time Price: $1.83 info
Change: +$0.360 (+24%) info
Market Cap: $5.149M info
PCSA
Oct 09, 2026, 4:02 PM EDT
Filing Type: S-3
Importance Score:
7
Price at Filing: $1.47
Real-time Price: $1.83 info
Change: +$0.360 (+24%) info
Market Cap: $5.149M info
PCSA
Oct 05, 2026, 7:21 AM EDT
Filing Type: 8-K/A
Importance Score:
8
Price at Filing: $1.60
Real-time Price: $1.83 info
Change: +$0.230 (+14%) info
Market Cap: $5.149M info